Pacific Biosciences of California, Inc. (PACB) Stock Price & Analysis

Pacific Biosciences of California, Inc. (PACB) closed at USD 2.83 on Wednesday, October 28, 2026, up 15.51% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 2.45; the Oct 28, 2026 session ranged USD 2.44–3.07 on volume of 34,969,050 shares. Market capitalization is $879.65M, with a 52-week range of USD 1.07–3.44 (NMS). Source: Nexqual, retrieved October 28, 2026 at 22:00 UTC.

Also available as compact Markdown for AI agents: nexqual.com/PACB.md

Key facts (PACB)

• Last four reported quarters (through Jun 30, 2026): revenue $159M, net income -$131M (-82.5% margin), free cash flow -$123M (SEC filings).
• Insider open-market sales, last ~7 months: 2 Form 4 filings, $2.1M; 1 not under a Rule 10b5-1 plan ($30K); 0 by opportunistic insiders, 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 2.75 on a 1–5 scale) (8 analysts), mean target USD 2.54 (range 1.25–3.05).
• Total return with dividends: 1Y +40.8% vs S&P 500 +13.6%; 5Y -89.3% vs S&P 500 +79.8%.
• Next earnings: 2026-11-04, EPS estimate USD -0.13, revenue estimate $39.5M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PACB)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (PACB)

P/S 5.5x · EV/Sales 8.1x · FCF yield -14.03% · Earnings yield -14.94% · Net debt $407M · EV $1.29B

Insider sales (SEC Form 4, open-market, last ~7 months) (PACB)

1 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (PACB)

Consensus Hold (mean 2.75 on a 1–5 scale), 8 analysts; mean target USD 2.54 (low 1.25, high 3.05).

Total return (dividends reinvested) (PACB)

PACB earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

PACB recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

PACB revenue by product line (quarter ended Jun 30, 2026)

PACB revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

PACB suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 25, 2026.

PACB company outlook (results filed Aug 5, 2026)

• “PacBio expects revenue for the full year 2026 to be in the range of $155 million to $165 million.”

Quoted word-for-word from the SEC 8-K results press release.

PACB analyst estimates and revisions

PACB options: expected move

Options price a move of about ±24.7% (±$0.75) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±10.3% on average.

30-day implied volatility 119.7% vs 133.9% realized over the last 30 trading days. Put/call ratio (volume) 0.02. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 28, 2026 at 22:00 UTC)

Technical Analysis (PACB)

Nexqual's technical model rates PACB "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 28, 2026 at 22:00 UTC.

Analyst Ratings (PACB)

Wall Street analysts rate PACB "Hold" based on 8 analysts, with a mean price target of USD 2.54 (range USD 1.25–3.05), per Nexqual as of October 28, 2026 at 22:00 UTC.

Earnings (PACB)

Recent Earnings History

Source: Nexqual, October 28, 2026 at 22:00 UTC.

Financials & Fundamentals (PACB)

Source: Nexqual, October 28, 2026 at 22:00 UTC.

Financial Health Score (PACB)

Nexqual rates Pacific Biosciences of California, Inc.'s overall financial health "Weak" across five dimensions, as of October 28, 2026 at 22:00 UTC.

Ownership (PACB)

Source: Nexqual, October 28, 2026 at 22:00 UTC.

Leadership (PACB)

Pacific Biosciences of California, Inc. is led by Mark Van Oene, CEO, President & Director, per Nexqual as of October 28, 2026 at 22:00 UTC.

Major Backers & Investors (PACB)

Notable institutional backers of Pacific Biosciences of California, Inc. include ARK Invest, Softbank Group Corporation, Sumitomo Mitsui Trust Group, Inc., according to Nexqual as of October 28, 2026 at 22:00 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 28, 2026 at 22:00 UTC.

From Pacific Biosciences of California, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• Customers purchase proprietary consumable products to run their PacBio systems, including our SMRT Cells and reagent kits.
• Our HiFi long-read sequencing protocol was built upon our SMRT sequencing systems, including consumables and software, and offers customized end-to-end workflows for different sequencing applications.
• Our proprietary SMRT sequencing technology enables the direct observation of DNA synthesis in real time by monitoring the activity of individual DNA polymerase molecules as they incorporate nucleotides into a growing DNA strand.
• We also innovate across end-to-end workflows to improve usability, as well as develop new applications for the advancement of human health.

Partnerships

• We provide required compliance training for employees, along with targeted, function-specific training where applicable, and ongoing learning through cross-functional collaboration and knowledge sharing.

Legal & Regulatory Risks (Item 1A, quoted)

• Our products are highly complex, have recurring support requirements and could have unknown defects or errors, which may give rise to claims against us or divert application of our resources from other purposes.
• Changes in tax law and differences in interpretation of tax laws and regulations could adversely impact our business and financial condition.
• The measures that we use to protect the security of and enforce our intellectual property and other proprietary rights may not be adequate, which could result in the loss of legal protection for, and thereby diminish the value of, such intellectual property and other rights.
• We have been, are currently, and could in the future be, subject to legal proceedings with third parties who may claim that our products infringe or misappropriate their intellectual property rights.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 22:00 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt